ArticlePolymer science & technology (Washington, D.C.)2025
NIR-II Light-Modulated Smart Drug Delivery System Utilizing Drug-Gated Nanocomposite Hydrogel for Boosting Anticancer Efficacy.
Article in Polymer science & technology (Washington, D.C.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- High Entanglement in Hydrogels: From Polymer Physics to Robust Mechanics.Polymer science & technology (Washington, D.C.) · 2026Review
- Advances in Nanobody-Based Platforms for Precision Cancer Diagnosis and Therapy.Polymer science & technology (Washington, D.C.) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Boosting the effectiveness of cancer therapies by fine-tuning the tumor microenvironment has become a pivotal focus in modern cancer research. Nevertheless, the quest for impactful strategies in this regard is still ongoing. In this study, a drug-gated nanocomposite hydrogel was developed using polyglutamic acid-modified gold nanorods (AuNRs) and cisplatin (CDDP) to facilitate controlled drug release and augment localized combined antitumor effectiveness. CDDP not only serves as a cross-linking agent for creating the gel networks but also functions as a gating site for the controlled release of aPD-L1. This drug delivery system features a dual-action release mechanism, triggered by the endogenous chloride ions and enhanced by external near-infrared heating by AuNRs. Significantly, CDDP is clearly sensitized by this localized photothermal effect, which also results in tumor ablation. Additionally, the induction of immunogenic cell death through photothermal chemotherapy further potentiates the efficacy of aPD-L1-involved immune checkpoint blockade. The results demonstrated that this therapeutic gel scaffold has good antitumor effects that synergize with the effects of immune-mediated hyperthermic chemotherapy and show promising application of a local stimulus-responsive drug-delivery system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.